Navigation Links
Medivir Reshapes Drug Discovery
Date:11/8/2007

Chooses Waters Synapt High Definition MS (HDMS) System to Aid

Decision-Making

MILFORD, Mass., Nov. 8 /PRNewswire-FirstCall/ -- Swedish-based biotechnology firm Medivir AB has chosen the Waters(R) Synapt(TM) HDMS System to hasten its drug discovery efforts in the area of protease inhibitor research and eventually help patients who suffer with herpes, hepatitis C, HIV, osteoporosis, osteoarthritis, and high blood pressure. Installed in June, the Synapt High Definition Mass Spectrometry(TM) (MS) System is yielding significant information that is assisting with the decision-making process and helping Medivir reach its drug discovery milestones.

"Medivir is constantly reviewing opportunities to improve research output both in terms of quantity and quality. This investment in the Waters Synapt HDMS instrument has been seen as a very important vehicle to increase research output and to provide high quality support for the discovery disciplines," said Medivir Vice President of Discovery Research, Bertil Samuellson, Ph.D.

In terms of helping Medivir advance its research, the Synapt HDMS(TM) System carries great potential.

"The sensitivity of this instrument is significantly greater than the average quadrupole time-of-flight instrument and gives us more complete metabolic profiles," says Kurt Benkestock, Senior Research Scientist, Analytical Chemistry Department, who supports many of Medivir's research efforts. "At one time, we relied on outside resources to give us the information we needed. Now with the Synapt HDMS System, we can acquire the data we need in house and move candidates into advanced development phases faster."

After carefully evaluating all its options, Medivir chose Waters Synapt HDMS System coupled to a Waters ACQUITY(R) UltraPerformance LC(R) (UPLC(R)) System over all the conventional high-resolution, two-dimensional LC-MS technologies offered by other mass spectrometry suppliers. "The reason we went with Waters Synapt System is that the instrument outperformed the others based on 22 performance criteria," says Benkestock.

Other intangible aspects of the selection process were important as well. "Waters is good at listening to its customers, understanding their requirements, and adding features and making improvements that help us meet our scientific requirements," added Benkestock.

Benkestock's plans for the Synapt HDMS System are far-ranging including structure elucidation of metabolites and impurities, ligand screening during early drug discovery, protein and peptide work, protein identification and studying post-translation modifications, and target characterization.

Medivir gave its employees a better look at the Synapt HDMS System during an inauguration event on Thursday, October 25 at corporate headquarters.

Waters introduced the Synapt HDMS System at the American Society of Mass Spectrometry annual meeting in Seattle in June of 2006. It is the first commercially-available mass spectrometer with the ability to analyze ions by their size, shape and charge in addition to mass.

Other customers include Cambridge University, Oxford University, Utrecht University, University of Leeds, Max Planck Institute, and the University of Warwick.

For more information: http://www.waters.com/hdms.

About Medivir AB (http://www.medivir.com)

Medivir aims to develop protease inhibitors into innovative pharmaceuticals to be used against major widespread diseases and improve the quality of life for a number of patient groups. Medivir has several partnerships with pharmaceutical companies and has one investigational drug in phase III clinical trials, three in phase II and two in phase I. Other protease projects are in the late preclinical stage.

About Waters Corporation (http://www.waters.com)

Waters Corporation (NYSE: WAT) creates business advantage for laboratory-dependent organizations by delivering practical and sustainable innovation to enable significant advancements in such areas as healthcare delivery, environmental management, food safety, and water quality worldwide.

Pioneering a connected portfolio of separations science, laboratory information management, mass spectrometry and thermal analysis, Waters technology breakthroughs and laboratory solutions provide an enduring platform for customer success.

With revenue of $1.28 billion in 2006 and 4,700 employees, Waters is driving scientific discovery and operational excellence for customers worldwide.

Waters, ACQUITY, UltraPerformance LC, UPLC, Synapt, High Definition MS, High Definition Mass Spectrometry, and HDMS are trademarks of Waters Corporation.

Media Contact:

Brian J. Murphy

Waters Corporation

508-482-2614

Brian_J_Murphy@waters.com


'/>"/>
SOURCE Waters Corporation
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Discovery of sugar sensor in intestine could benefit diabetes
2. Discovery suggests location of genes for breast density, a strong risk factor for breast cancer
3. Stem cell research produces a key discovery for Fragile X Syndrome
4. Welch Foundation gives $1.6 million for drug discovery research
5. New discovery leaves blood-doping athletes scratching their heads
6. Chemical Diversity Initiates International Prostrate Cancer Discovery Partnership
7. New discovery leaves blood-doping athletes scratching their heads
8. Discovery of widespread tumor growth gene holds promise for effective anti-cancer treatment
9. Discovery supports theory of Alzheimers disease as form of diabetes
10. Discovery Health CME Explores the Benefits and Risks of Aspirin in Aspirin Therapy: Maximizing the Benefits
11. New discovery may improve treatment of one of the worlds leading causes of blindness
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... ... February 08, 2016 , ... Stephanie Hebert Insurance ... beginning of a new charity campaign. As part of their ongoing community involvement ... In the belief that children deserve a voice, and in the spirit of ...
(Date:2/8/2016)... ... February 08, 2016 , ... If you are feeling that your ... are not alone. According to the Center for Disease Control and Prevention (CDC), 34.9% ... diabetes and certain types of cancer, some of the leading causes of preventable death. ...
(Date:2/8/2016)... ... 08, 2016 , ... Local insurance agency Dennis Fuller & ... has initiated a fundraiser for a two year old little girl named Bella, ... To support this beautiful child who is facing life’s journey without her loving ...
(Date:2/8/2016)... ... February 08, 2016 , ... ... While a significant number of women and men with eating disorders report a ... that best predicts the development of an eating disorder. , At the ...
(Date:2/8/2016)... (PRWEB) , ... February 08, 2016 , ... ... excited to share this important news! AHCC and the Home Health and Hospice ... Clinic, CMS' designee for official ICD coding guidance and clarifications, to address concerns ...
Breaking Medicine News(10 mins):
(Date:2/8/2016)... 2016  Avista Pharma Solutions ("Avista Pharma") announced today ... Financial Officer (CFO). Mr. Setzer is a finance and ... various roles within growing technology and life science companies. ... Executive Director of Finance at INC Research, a publicly ... . Previously, Mr. Setzer served as CFO of ...
(Date:2/8/2016)... Velano Vascular, a medical technology company transforming ... their practitioners, announced today that the company has raised ... the proceeds from this financing, an extension of a ... to support the development and commercialization of the company,s ... Philadelphia , and a number ...
(Date:2/8/2016)... Fla. , Feb. 8, 2016 Vestagen ... marketing high performance apparel for healthcare and other demanding ... Chief Executive Officer. He replaces Dale Pfost ... remains Chairman. Mr. Bold is also joining Vestagen,s Board ... a new class of active barrier technologies that combines ...
Breaking Medicine Technology: